Tag: Xgeva

In some studies, patients who stop denosumab (Xgeva) have a vertebral fracture rate that can increase nearly sixfold, returning to the level of untreated patients [1.8.1]. Understanding what happens when you stop Xgeva is critical for managing bone health.

By 2025, experts predict osteoporosis will be responsible for three million fractures and cost $25.3 billion annually [1.7.1, 1.7.2]. Two drugs often discussed for bone health are Prolia and Xgeva. Understanding the question of 'Which is better, Prolia or Xgeva?' requires a look at their distinct uses and dosages.

Globally, millions of people with specific cancer types face a heightened risk of serious bone problems. The Xgeva injection is a targeted therapy designed to prevent these complications and treat other rare bone conditions by inhibiting a key protein responsible for bone breakdown.

According to the National Cancer Institute, Xgeva (denosumab) is a monoclonal antibody used to prevent or treat specific bone problems in cancer patients. It helps to reduce the risk of fractures, spinal cord compression, and other skeletal-related events.